5- CACGAAACTACCTTCAACTCC-3 beta actin-r 5- CATACTCCTGCTTGCTGATC-3 GAPDH-F GAPDH-R

Μέγεθος: px

Εμφάνιση ξεκινά από τη σελίδα:

Download "5- CACGAAACTACCTTCAACTCC-3 beta actin-r 5- CATACTCCTGCTTGCTGATC-3 GAPDH-F GAPDH-R"

Θέμις Καλογιάννης
6 χρόνια πριν
Προβολές:

1 Table S1 Primers used in this work LncPPARδ-F 5- AGGATCCCAAGGCAGAAGTT -3 LncPPARδ-R 5- GAATAGAAAGGCGGGAAAGG -3 PPARδ-F 5- CACCCAGTGTCCTTCCATCT -3 PPARδ-R 5- CAGAATTGGGTGTGCTGCTT -3 ADRP-F 5- ACAACCGAGTGTGGTGACTC -3 ADRP-R 5- TCTTCACACCGTTCTCTGCC -3 ANGPTL4-F 5-CCTCTCCGTACCCTTCTCCA-3 ANGPTL4-R 5-AAACCACCAGCCTCCAGAGA-3 beta actin-f 5- CACGAAACTACCTTCAACTCC-3 beta actin-r 5- CATACTCCTGCTTGCTGATC-3 GAPDH-F GAPDH-R 5- AGCCACATCGCTCAGACAC-3 5- GCCCAATACGACCAAATCC-3 LncPPARδ-siRNA sirna-nc 5-CCUUUCCCGCCUUUCUAUUTT-3 5-UUCUCCGAACGUGUCACGUTT-3 PPARδ: peroxisome proliferator activator receptor delta; ADRP: perilinpin2 (PLIN2); ANGPTL4: Angiopoietin-like 4. Table S2. Clinical characteristics and outcome of 15 CAD patients and 15 control subjects. Characteristics CAD(n=15) Control (n=15) P-value Age (years) 62.17± ± Sex (male/female) 15/0 15/0 Physical data Heart rate (bpm) 74.60± ± Height (cm) ± ± BMI (kg/m2) 23.87± ± Historical data Diabetes mellitus 0/15 0/15 (Y/N) Arterial 0/15 0/15 hypertension (Y/N) Dyslipidemia (Y/N) 0/15 0/15 Laboratory data Glucose (mmol/l) 5.17± ± TC (mmol/l) 4.23± ± TG (mmol/l) 1.47± ± HDL (mmol/l) 1.14± ± LDL (mmol/l) 2.44± ± ApoA1 (g/l) 1.41± ± ApoB (g/l) 0.94± ± T-Bil (mol/l) 14.58± ± D-Bil (mol/l) 3.02± ± TBA (mol/l) 4.81± ± Total protein (g/l) 65.71± ± Albumin (g/l) 39.79± ± A/G 1.70± ± AST (units/l) 22.55± ± AST/ALT 1.24± ± ALP (units/l) 94.24± ± GGT (units/l) 31.27± ±

2 LDH (units/l) ± ± PO4 (mmol/l) 1.32± ± Na+ (mmol/l) ± ± K+ (mmol/l) 4.03± ± Cl- (mmol/l) ± ± CO2 (mmol/l) 24.27± ± Ca2+(mmol/l) 2.37± ± AG (mmol/l) 12.70± ± Urea (mmol/l) 19.80± ± U/C 18.32± ± Uric acid (mol/l) ± ± RBC 1012/l 4.70± ± WBC 109/l 6.29± ± PLT 109/l ± ± HGB (g/l) ± ± Smoking status current smoker 4/11 3/12.50 Never smoke 7/8 6/9.71 r Drinking 4/11 4/11.50 Treatment ACEI use (Y/N) 0/15 0/15 ARB use (Y/N) 0/15 0/15 Beta-blocker use 0/13 0/15 (Y/N) CCB use (Y/N) 0/15 0/15 Diuretics use (Y/N) 0/15 0/15 Statins use (Y/N) 0/15 0/15 Antiplatelet therapy 15/15 0/15 <.001 CAD, coronary artery heart disease, BMI, body mass index (kg/m2), TC, total cholesterol; TG, triglyceride; HDL, high density lipoprotein; LDL, low density lipoprotein; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; T-Bil, total bilirubin; D-Bil, direct bilirubin; TBA, total bile acid; A/G, albumin/globulin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; -GGP, gamma-glutamyl transpeptidase; LDH, lactate dehydrogenase; AG, anion gap; U/C, urea/creatinine; RBC, red blood cell; WBC, white blood cell; PLT, platelet; HGB, hemoglobin; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker. Data are presented as mean ± SD, n = numbers of patients. P< 0.05 was considered significant. Table S3. Clinical characteristics and outcome of 20 patients and 20 control subjects. Characteristics CAD(n=20) Control (n=20) P-value Age (years) 66.25± ± Sex (male, female) 10/10 12/8.38 Physical data Heart rate (bpm) 76.70± ± Height (cm) ± ± BMI (kg/m2) 21.71± ± Historical data

3 Diabetes mellitus 3/17 2/18 >.99 Arterial 10/10 6/14.17 hypertension (Y/N) Dyslipidaemia 12/8 12/8.63 Laboratory data Glucose (mmol/l) 4.87± ± TC (mmol/l) 4.32± ± TG (mmol/l) 2.22± ± HDL (mmol/l) 1.12± ± LDL (mmol/l) 2.63± ± ApoA1 (g/l) 1.31± ± ApoB (g/l) 0.87± ± T-Bil (mol/l) 14.65± ± D-Bil (mol/l) 2.91± ± TBA (mol/l) 4.87± ± Total protein (g/l) 65.63± ±6.97 >.99 Albumin (g/l) 39.70± ± A/G 1.54± ± AST (units/l) 22.40± ± AST/ALT 1.19± ± ALP (units/l) 84.68± ± GGT (units/l) 26.74± ± LDH (units/l) ± ±33.93 >.99 PO4 (mmol/l) 1.17± ± Na+ (mmol/l) ± ± K+ (mmol/l) 3.91± ± Cl- (mmol/l) ± ± CO2 (mmol/l) 24.09± ± Ca2+ (mmol/l) 2.27± ± AG (mmol/l) 11.61± ± Urea (mmol/l) 20.05± ± U/C 19.30± ± Uric acid (mol/l) ± ± RBC 1012/l 4.41± ± WBC 109/l 6.95± ± PLT 109/l ± ± HGB (g/l) ± ± Smoking status current smoker 3/17 6/14.23 Never smoker 6/14 6/14.63 Drinking 2/18 5/15.20 Treatment ACEI use 4/16 6/14.36 ARB use 7/13 4/16.24 Beta-blocker use 2/18 0/20.24 CCB use 5/15 5/15.64 Diuretics use (Y/N) 0/20 0/20

4 Statins use 10/10 12/8.38 Antiplatelet therapy 8/12 8/12.63 LncPPARδ 1.29± ±0.42 <.001 CAD, coronary artery heart disease, BMI, body mass index (kg/m2), TC, total cholesterol; TG, triglyceride; HDL, high density lipoprotein; LDL, low density lipoprotein; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; T-Bil, total bilirubin; D-Bil, direct bilirubin; TBA, total bile acid; A/G, albumin/globulin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; -GGP, gamma-glutamyl transpeptidase; LDH, lactate dehydrogenase; AG, anion gap; U/C, urea/creatinine; RBC, red blood cell; WBC, white blood cell; PLT, platelet; HGB, hemoglobin; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker. Data are presented as mean ± SD, n = numbers of patients. P< 0.05 was considered significant. Student s-test, 2 2 contingency table analysis of x2, others by Mann-Whitney U test. Table S4. Clinical characteristics and outcome of 211 CAD patients and 171 control subjects (original set). Characteristics CAD(n=211) Control (n=171) P-value Age (years) 65.24± ±10.67 <.001 Sex (male, female) 134/77 85/ Physical data Heart rate (bpm) 72.94± ± Height (cm) ± ± BMI (kg/m2) 23.29± ± Historical data Diabetes mellitus 41/170 34/137 >.99 Arterial hypertension 112/99 45/ Dyslipidaemia (Y/N) 119/92 107/64.22 Laboratory data Glucose (mmol/l) 5.09± ± TC (mmol/l) 4.57± ± TG (mmol/l) 1.74± ± HDL (mmol/l) 1.09± ± LDL (mmol/l) 2.79± ± ApoA1 (g/l) 1.56± ± ApoB (g/l) 0.86± ± T-Bil (mol/l) 13.20± ± D-Bil (mol/l) 2.51± ± TBA (mol/l) 5.93± ± Total protein (g/l) 64.66± ± Albumin (g/l) 39.37± ± A/G 1.59± ± AST (units/l) 28.05± ± AST/ALT 1.30± ± ALP (units/l) 84.47± ± GGT (units/l) 27.98± ± LDH (units/l) ± ± PO4 (mmol/l) 1.17± ± Na+ (mmol/l) ± ±

5 K+ (mmol/l) 3.98± ± Cl- (mmol/l) ± ± CO2 (mmol/l) 24.35± ± Ca2+ (mmol/l) 2.22± ± AG (mmol/l) 12.04± ± Urea (mmol/l) 8.12± ± U/C 16.98± ± Uric acid (mol/l) ± ± RBC 1012/l 4.38± ± WBC 109/l 6.52± ± PLT 109/l ± ± HGB (g/l) ± ± Smoking status current smoker (Y/N) 59/152 20/151 <.001 Never smoker 127/84 118/53.05 Drinking 50/161 26/ Treatment ACEI use 39/172 26/ ARB use 70/141 26/145 <.001 Beta-blocker use 17/194 1/170 <.001 CCB use 87/124 28/143 <.001 Diuretics use 1/210 0/ Statins use 136/75 99/72.11 Antiplatelet therapy 85/126 58/ LncPPARδ 1.47± ±0.51 <.001 CAD, coronary artery heart disease, BMI, body mass index (kg/m2), TC, total cholesterol; TG, triglyceride; HDL, high density lipoprotein; LDL, low density lipoprotein; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; T-Bil, total bilirubin; D-Bil, direct bilirubin; TBA, total bile acid; A/G, albumin/globulin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; -GGP, gamma-glutamyl transpeptidase; LDH, lactate dehydrogenase; AG, anion gap; U/C, urea/creatinine; RBC, red blood cell; WBC, white blood cell; PLT, platelet; HGB, hemoglobin; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker. Data are presented as mean ± SD, n = numbers of patients. P< 0.05 was considered significant. Student s-test, 2 2 contingency table analysis of x2, others by Mann-Whitney U test. Table S5-1. Average sensitivity and specificity for the diagnosis CAD by LncPPARδ in test group (100 times). Disease+ve % 80.16% Disease-ve Total ve, positive, -ve, negative. Table S5-2. Optimal sensitivity and specificity for the diagnosis CAD by LncPPARδ in test group (79th).

6 Disease+ve % 94.00% Disease-ve Total ve, positive, -ve, negative, 79th, optimal sampling time. Table S6-1. Average sensitivity and specificity for the diagnosis CAD by LncPPARδ and combination of the four factors in the test set. Disease+ve % 74.86% Disease-ve Total ve, positive, -ve, negative. Table S6-2. Optimal sensitivity and specificity for the diagnosis CAD by LncPPARδ and combination of the four factors in the test set (32th). Disease+ve % 78.00% Disease-ve Total ve, positive, -ve, negative, 79th, optimal sampling time. Table S7-1. Sensitivity and specificity for the diagnosis CAD by LncPPARδ in the independent set (79th). Disease+ve % 72.00% Disease-ve Total th, optimal sampling time. Table S7-2. Sensitivity and specificity for the diagnosis CAD by LncPPARδ and combination of the four factors in the independent set (32th). Disease+ve % 66.00% Disease-ve Total th, optimal sampling time. Table S8. Clinical Characteristics and Outcome of patients and control subjects in the independent set. Characteristics CAD(50) Control(40) P-value Age (years) 65.97± ± Sex (male, female) 28/22 18/22.26 Physical data

7 Heart rate (bpm) 69.73± ± Height (cm) ± ± BMI(kg/m2) 23.86± ± Historical data Diabetes mellitus 22/28 17/23.90 Arterial hypertension 26/24 19/21.39 Dyslipidaemia (Y/N) 31/19 25/15.32 Laboratory data Glucose (mmol/l) 4.96± ± TC (mmol/l) 4.52± ± TG (mmol/l) 1.64± ± HDL (mmol/l) 1.04± ± LDL (mmol/l) 2.72± ± ApoA1 (g/l) 1.34± ± ApoB (g/l) 1.16± ± T-Bil (mol/l) 14.70± ± D-Bil (mol/l) 2.46± ± TBA (mol/l) 4.18± ± Total protein (g/l) 66.31± ± Albumin (g/l) 39.98± ± A/G 1.57± ± AST (units/l) 20.17± ± AST/ALT 1.28± ± ALP (units/l) 86.10± ± GGT (units/l) 21.83± ± LDH (units/l) ± ± PO4 (mmol/l) 1.11± ± Na+ (mmol/l) ± ± K+ (mmol/l) 4.05± ± Cl- (mmol/l) ± ± CO2 (mmol/l) 24.42± ± Ca2+ (mmol/l) 2.21± ± AG (mmol/l) 11.45± ± Urea (mmol/l) 5.27± ± U/C 18.33± ± Uric acid ( mol/l) ± ± RBC 1012/l 4.36± ± WBC 109/l 6.85± ± PLT 109/l ± ± HGB (g/l) ± ± Smoking status current smoker (Y/N) Never smoker (Y/N) 13/37 8/ /28 20/20.08 Treatment ACEI use 17/33 9/31.22 ARB use 19/31 14/26.33 Beta-blocker use 13/37 10/30.21 CCB use 22/28 16/24.34

8 Diuretics use (Y/N) 0/50 0/50 Stati ns use 30/20 20/20.19 Antiplatelet therapy 21/29 12/28.03 CAD, coronary artery heart disease, BMI, body mass index (kg/m2), TC, total cholesterol; TG, triglyceride; HDL, high density lipoprotein; LDL, low density lipoprotein; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; T-Bil, total bilirubin; D-Bil, direct bilirubin; TBA, total bile acid; A/G, albumin/globulin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; -GGP, gamma-glutamyl transpeptidase; LDH, lactate dehydrogenase; AG, anion gap; U/C, urea/creatinine; RBC, red blood cell; WBC, white blood cell; PLT, platelet; HGB, hemoglobin; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker. Data are presented as mean ± SD, n = numbers of patients. P< 0.05 was considered significant. Student s-test, 2 2 contingency table analysis of x2, others by Mann-Whitney U test. Table S9. Sex and age of patients and control subjects with different CVD or metabolic diseases Diseases Sex Age (years) p1 p2 (male/female) Normal 10/ ± CAD 10/ ±9.75 Arrhythmia 5/ ± Valvular 5/ ± disease Dilated 4/ ± cardiomyopath y Hyperlipidemi 5/ ± a Hypertension 5/ ± Type 2 7/ ± diabetes mellitus Abdominal 1/ ± aortic aneurysm Viral myocarditis 4/ ± CAD, coronary artery heart disease, CVD, cardiovascular diseases. Data are presented as mean ± SD or n. n = numbers of patients. P< 0.05 was considered significant. Student s-test, 2 2 contingency table analysis of x2.

Σχετικά έγγραφα

Supplemental tables and figures

Supplemental tables and figures Supplemental Table S1. Demographic and clinical parameters by quartiles of white Variables blood cell count. WBC quartiles( 1 9 cells/l) Q1(.6-5.3, n=2587) Q2(5.4-6.3, n=263)